<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Summary of Conferences 2016</title>
  <meta name="description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here.">
  <meta name="generator" content="bookdown 0.3.11 and GitBook 2.6.7">

  <meta property="og:title" content="Summary of Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="github-repo" content="shanmdphd/shanmdphd.github.io" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Summary of Conferences 2016" />
  
  <meta name="twitter:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han, M.D./Ph.D.">


<meta name="date" content="2017-03-21">

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="translation-and-convergence-for-future-medicine.html">
<link rel="next" href="prism-2016.html">
<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="section-2.html"><a href="section-2.html"><i class="fa fa-check"></i><b>2</b> 심장내과</a></li>
<li class="chapter" data-level="3" data-path="-3.html"><a href="-3.html"><i class="fa fa-check"></i><b>3</b> 심장내과 3부</a></li>
<li class="chapter" data-level="4" data-path="cancer-immunotherapy.html"><a href="cancer-immunotherapy.html"><i class="fa fa-check"></i><b>4</b> Cancer immunotherapy</a></li>
<li class="chapter" data-level="5" data-path="bioimaging-2016-04-29.html"><a href="bioimaging-2016-04-29.html"><i class="fa fa-check"></i><b>5</b> Bioimaging 2016-04-29</a></li>
<li class="chapter" data-level="6" data-path="-fda-.html"><a href="-fda-.html"><i class="fa fa-check"></i><b>6</b> 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 |</a><ul>
<li class="chapter" data-level="6.1" data-path="-fda-.html"><a href="-fda-.html#-center-for-bioimaging-of-new-drug-development-amc"><i class="fa fa-check"></i><b>6.1</b> 김정곤 Center for Bioimaging of New Drug Development AMC</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>7</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="7.1" data-path="kscpt.html"><a href="kscpt.html#first-session"><i class="fa fa-check"></i><b>7.1</b> First Session</a><ul>
<li class="chapter" data-level="7.1.1" data-path="kscpt.html"><a href="kscpt.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>7.1.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="7.1.2" data-path="kscpt.html"><a href="kscpt.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>7.1.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="7.1.3" data-path="kscpt.html"><a href="kscpt.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>7.1.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="7.2" data-path="kscpt.html"><a href="kscpt.html#second-session"><i class="fa fa-check"></i><b>7.2</b> Second Session</a><ul>
<li class="chapter" data-level="7.2.1" data-path="kscpt.html"><a href="kscpt.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>7.2.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="7.2.2" data-path="kscpt.html"><a href="kscpt.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>7.2.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="7.2.3" data-path="kscpt.html"><a href="kscpt.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>7.2.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="7.2.4" data-path="kscpt.html"><a href="kscpt.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>7.2.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="8" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>8</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="8.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#plenary-session-ii--rd-"><i class="fa fa-check"></i><b>8.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="8.1.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1--------"><i class="fa fa-check"></i><b>8.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="8.1.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----"><i class="fa fa-check"></i><b>8.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="8.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#parallel-session-i--chairperson--"><i class="fa fa-check"></i><b>8.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="8.2.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>8.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="8.2.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>8.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="8.2.3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-3-------"><i class="fa fa-check"></i><b>8.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="9" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>9</b> ACREP</a><ul>
<li class="chapter" data-level="9.1" data-path="acrep.html"><a href="acrep.html#observational-study"><i class="fa fa-check"></i><b>9.1</b> Observational Study</a><ul>
<li class="chapter" data-level="9.1.1" data-path="acrep.html"><a href="acrep.html#contents"><i class="fa fa-check"></i><b>9.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="9.2" data-path="acrep.html"><a href="acrep.html#observational-study-pitfall-----"><i class="fa fa-check"></i><b>9.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="9.2.1" data-path="acrep.html"><a href="acrep.html#experimental-study-yes"><i class="fa fa-check"></i><b>9.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="9.2.2" data-path="acrep.html"><a href="acrep.html#experimental-study-no"><i class="fa fa-check"></i><b>9.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="9.2.3" data-path="acrep.html"><a href="acrep.html#contents-1"><i class="fa fa-check"></i><b>9.2.3</b> Contents</a></li>
<li class="chapter" data-level="9.2.4" data-path="acrep.html"><a href="acrep.html#conclusion"><i class="fa fa-check"></i><b>9.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9.3" data-path="acrep.html"><a href="acrep.html#diagnostic-test-biomarker-study"><i class="fa fa-check"></i><b>9.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="9.3.1" data-path="acrep.html"><a href="acrep.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>9.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="9.3.2" data-path="acrep.html"><a href="acrep.html#contents---biomarker"><i class="fa fa-check"></i><b>9.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="9.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>9.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="9.5" data-path="acrep.html"><a href="acrep.html#----clinical-prediction-model-individual-riskoutcome-probability--"><i class="fa fa-check"></i><b>9.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="9.6" data-path="acrep.html"><a href="acrep.html#web-r.org"><i class="fa fa-check"></i><b>9.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="9.6.1" data-path="acrep.html"><a href="acrep.html#contents-2"><i class="fa fa-check"></i><b>9.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="10" data-path="prism-2016.html"><a href="prism-2016.html"><i class="fa fa-check"></i><b>10</b> Prism 2016</a><ul>
<li class="chapter" data-level="10.1" data-path="prism-2016.html"><a href="prism-2016.html#morning-session"><i class="fa fa-check"></i><b>10.1</b> Morning Session</a><ul>
<li class="chapter" data-level="10.1.1" data-path="prism-2016.html"><a href="prism-2016.html#lim-covariate-model"><i class="fa fa-check"></i><b>10.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="10.1.2" data-path="prism-2016.html"><a href="prism-2016.html#fda---lee"><i class="fa fa-check"></i><b>10.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="10.1.3" data-path="prism-2016.html"><a href="prism-2016.html#pfizer"><i class="fa fa-check"></i><b>10.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="prism-2016.html"><a href="prism-2016.html#afternoon-session"><i class="fa fa-check"></i><b>10.2</b> Afternoon Session</a><ul>
<li class="chapter" data-level="10.2.1" data-path="prism-2016.html"><a href="prism-2016.html#kim"><i class="fa fa-check"></i><b>10.2.1</b> Kim</a></li>
<li class="chapter" data-level="10.2.2" data-path="prism-2016.html"><a href="prism-2016.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>10.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="10.2.3" data-path="prism-2016.html"><a href="prism-2016.html#mbdd"><i class="fa fa-check"></i><b>10.2.3</b> MBDD</a></li>
<li class="chapter" data-level="10.2.4" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>10.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="10.2.5" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>10.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="11" data-path="MFDS.html"><a href="MFDS.html"><i class="fa fa-check"></i><b>11</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="11.1" data-path="MFDS.html"><a href="MFDS.html#session-1-rare-diseases-in-korea-status-research-experiences"><i class="fa fa-check"></i><b>11.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="11.1.1" data-path="MFDS.html"><a href="MFDS.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>11.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="11.1.2" data-path="MFDS.html"><a href="MFDS.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>11.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="11.2" data-path="MFDS.html"><a href="MFDS.html#session-2-global-regulatory-experiences-in-orphan-drug-development"><i class="fa fa-check"></i><b>11.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="11.2.1" data-path="MFDS.html"><a href="MFDS.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>11.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="11.2.2" data-path="MFDS.html"><a href="MFDS.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>11.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="11.3" data-path="MFDS.html"><a href="MFDS.html#session-3-lessons-and-learned-rd-for-rare-disease"><i class="fa fa-check"></i><b>11.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a><ul>
<li class="chapter" data-level="11.3.1" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-i"><i class="fa fa-check"></i><b>11.3.1</b> Lessons from an orphan drug development (I)</a></li>
<li class="chapter" data-level="11.3.2" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-ii"><i class="fa fa-check"></i><b>11.3.2</b> Lessons from an orphan drug development (II)</a></li>
<li class="chapter" data-level="11.3.3" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-inflammatory-bowel-disease-asan-medical-center"><i class="fa fa-check"></i><b>11.3.3</b> Case studies on inflammatory bowel disease Asan Medical Center</a></li>
<li class="chapter" data-level="11.3.4" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-drug-targets-in-rare-ultra-rare-genetic-disorders"><i class="fa fa-check"></i><b>11.3.4</b> Case studies on drug targets in rare &amp; ultra-rare genetic disorders</a></li>
</ul></li>
<li class="chapter" data-level="11.4" data-path="MFDS.html"><a href="MFDS.html#session-4-asan-initia-tives-for-rare-disease"><i class="fa fa-check"></i><b>11.4</b> Session 4 Asan initia tives for rare disease</a><ul>
<li class="chapter" data-level="11.4.1" data-path="MFDS.html"><a href="MFDS.html#leverage-big-data-to-better-understand-rare-disease-states-and-patient-needs-rare-disease-registry-research-experience"><i class="fa fa-check"></i><b>11.4.1</b> Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience)</a></li>
<li class="chapter" data-level="11.4.2" data-path="MFDS.html"><a href="MFDS.html#align-commercial-and-development-team-to-forecast-success-through-prism"><i class="fa fa-check"></i><b>11.4.2</b> Align commercial and development team to forecast success through “PRISM”</a></li>
<li class="chapter" data-level="11.4.3" data-path="MFDS.html"><a href="MFDS.html#knowledge-and-perceptions-of-clinical-research-of-patients-suffering-from-rare-diseases"><i class="fa fa-check"></i><b>11.4.3</b> Knowledge and perceptions of clinical research of patients suffering from rare diseases</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="12" data-path="toxicology-2016.html"><a href="toxicology-2016.html"><i class="fa fa-check"></i><b>12</b> Toxicology 2016</a><ul>
<li class="chapter" data-level="12.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#key-links"><i class="fa fa-check"></i><b>12.1</b> Key links</a></li>
<li class="chapter" data-level="12.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-i-2016-08-22"><i class="fa fa-check"></i><b>12.2</b> Session I 2016-08-22</a><ul>
<li class="chapter" data-level="12.2.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.2.1</b> 독성학 개론 및 발현기전 !!!!</a></li>
<li class="chapter" data-level="12.2.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.2"><i class="fa fa-check"></i><b>12.2.2</b> 면역독성 !</a></li>
<li class="chapter" data-level="12.2.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#-"><i class="fa fa-check"></i><b>12.2.3</b> 독성시험과 통계 !!</a></li>
<li class="chapter" data-level="12.2.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.4"><i class="fa fa-check"></i><b>12.2.4</b> 독성병리 !!</a></li>
<li class="chapter" data-level="12.2.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.2.5</b> 비임상시험결과의 임상시험 연계 !!!!</a></li>
</ul></li>
<li class="chapter" data-level="12.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-ii-2016-08-23"><i class="fa fa-check"></i><b>12.3</b> Session II 2016-08-23</a><ul>
<li class="chapter" data-level="12.3.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.3.1</b> 오믹스 기반을 이용한 독성평가 !</a></li>
<li class="chapter" data-level="12.3.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.2</b> 독성동태 및 대사 !!!</a></li>
<li class="chapter" data-level="12.3.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.3</b> 유전독성 및 발암성 !!</a></li>
<li class="chapter" data-level="12.3.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.4"><i class="fa fa-check"></i><b>12.3.4</b> 신경독성 !</a></li>
<li class="chapter" data-level="12.3.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.5</b> 식품의 위해도 평가 !</a></li>
<li class="chapter" data-level="12.3.6" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.6"><i class="fa fa-check"></i><b>12.3.6</b> 생식발생독성 !</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="13" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><i class="fa fa-check"></i><b>13</b> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</a><ul>
<li class="chapter" data-level="13.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#drug-discovery-and-preclinical-candidate-selection"><i class="fa fa-check"></i><b>13.1</b> Drug discovery and preclinical candidate selection</a><ul>
<li class="chapter" data-level="13.1.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#-1st"><i class="fa fa-check"></i><b>13.1.1</b> 김재은 (1ST)</a></li>
</ul></li>
<li class="chapter" data-level="13.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#preclinical-development-and-ind-gono-go-decision-using-case-studies"><i class="fa fa-check"></i><b>13.2</b> Preclinical development and IND go/no-go decision (using case studies)</a></li>
<li class="chapter" data-level="13.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies"><i class="fa fa-check"></i><b>13.3</b> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</a></li>
<li class="chapter" data-level="13.4" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-pharmacology"><i class="fa fa-check"></i><b>13.4</b> Clinical Pharmacology</a></li>
<li class="chapter" data-level="13.5" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies"><i class="fa fa-check"></i><b>13.5</b> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</a><ul>
<li class="chapter" data-level="13.5.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#experience-of-sop-development-pv-training-sharing-pv-audit-finding"><i class="fa fa-check"></i><b>13.5.1</b> Experience of SOP development &amp; PV training/ Sharing PV audit finding</a></li>
<li class="chapter" data-level="13.5.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#establishment-and-application-of-safety-database-system"><i class="fa fa-check"></i><b>13.5.2</b> Establishment and Application of Safety Database System:</a></li>
</ul></li>
<li class="chapter" data-level="13.6" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#open-innovation-in-drug-development"><i class="fa fa-check"></i><b>13.6</b> Open innovation in drug development</a></li>
<li class="chapter" data-level="13.7" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-development-strategy-and-plan-workshop"><i class="fa fa-check"></i><b>13.7</b> Clinical development strategy and plan workshop</a><ul>
<li class="chapter" data-level="13.7.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#course-intro---understanding-tpp-and-hcv"><i class="fa fa-check"></i><b>13.7.1</b> Course intro - Understanding TPP and HCV</a></li>
<li class="chapter" data-level="13.7.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#candidate-selection-through-poc"><i class="fa fa-check"></i><b>13.7.2</b> Candidate selection through PoC</a></li>
<li class="chapter" data-level="13.7.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#late-phase-development-commercialization"><i class="fa fa-check"></i><b>13.7.3</b> Late phase Development &amp; Commercialization</a></li>
<li class="chapter" data-level="13.7.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>13.7.4</b> 국내 사례 소개 및 질의/응답</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="14" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html"><i class="fa fa-check"></i><b>14</b> The 2nd A3 Pharmacometrics Symposium</a><ul>
<li class="chapter" data-level="14.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#young-scientist-session"><i class="fa fa-check"></i><b>14.1</b> Young Scientist Session</a><ul>
<li class="chapter" data-level="14.1.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-of-mycoplasma-tuberculosis-biomarkders-for-cure"><i class="fa fa-check"></i><b>14.1.1</b> Modeling of mycoplasma tuberculosis biomarkders for cure</a></li>
<li class="chapter" data-level="14.1.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#integrative-pkpd-modling-and-simulation-of-amenamevir-for-treatment-of-recurrent-genital-herpes"><i class="fa fa-check"></i><b>14.1.2</b> Integrative PKPD modling and simulation of Amenamevir for treatment of recurrent genital herpes</a></li>
<li class="chapter" data-level="14.1.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#model-based-meta-analysis-to-quantify-and-compare-the-efficacy-of-non-hormonal-drugs-on-menopausal-hot-flashes"><i class="fa fa-check"></i><b>14.1.3</b> Model Based Meta-Analysis to quantify and compare the efficacy of non-hormonal drugs on menopausal Hot flashes</a></li>
<li class="chapter" data-level="14.1.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#dosing-optimization-in-obesity-using-pharmacometrics-approach-population-pk-and-pd-of-meropenem-in-non-obese-obese-and-mobidly-obese-patients"><i class="fa fa-check"></i><b>14.1.4</b> Dosing optimization in obesity using pharmacometrics approach: population PK and PD of meropenem in non-obese, obese and mobidly obese patients</a></li>
</ul></li>
<li class="chapter" data-level="14.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-session"><i class="fa fa-check"></i><b>14.2</b> Application Session</a><ul>
<li class="chapter" data-level="14.2.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-application-of-pharmacometrics-in-individual-therapy-in-china"><i class="fa fa-check"></i><b>14.2.1</b> The application of pharmacometrics in individual therapy in China</a></li>
<li class="chapter" data-level="14.2.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pd-model-fo-bayesian-prediction-of-myelosuppression-rpofiles-based-on-routine-clinical-data-after-gemcitabine-and-carboplatin-treatment"><i class="fa fa-check"></i><b>14.2.2</b> PD model fo Bayesian Prediction of myelosuppression rpofiles based on routine clinical data after gemcitabine and carboplatin treatment</a></li>
<li class="chapter" data-level="14.2.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-and-validating-chronic-pharmacological-manupulation-of-circadian-rhythms"><i class="fa fa-check"></i><b>14.2.3</b> Modeling and validating chronic pharmacological manupulation of circadian rhythms</a></li>
<li class="chapter" data-level="14.2.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-of-pkpd-modeling-and-simulation-in-antiviral-drug-development"><i class="fa fa-check"></i><b>14.2.4</b> Application of PK/PD modeling and simulation in antiviral drug development</a></li>
<li class="chapter" data-level="14.2.5" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pharmacometrics-in-clinical-practice-pop-pk-analysis-of-febuxostat-in-patients-with-severe-renal-impairment"><i class="fa fa-check"></i><b>14.2.5</b> pharmacometrics in clinical practice: pop PK analysis of febuxostat in patients with severe renal impairment</a></li>
</ul></li>
<li class="chapter" data-level="14.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#regulation"><i class="fa fa-check"></i><b>14.3</b> Regulation</a><ul>
<li class="chapter" data-level="14.3.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-new-japanese-guideline-on-population-pk-and-pd-analysis"><i class="fa fa-check"></i><b>14.3.1</b> The new Japanese guideline on population PK and PD analysis</a></li>
<li class="chapter" data-level="14.3.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#how-to-increase-the-number-of-population-pk-analysis-reports-submitted-to-mfds-in-korea"><i class="fa fa-check"></i><b>14.3.2</b> How to increase the number of population PK analysis reports submitted to MFDS in Korea</a></li>
<li class="chapter" data-level="14.3.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#ema-regulations-on-meling-issues"><i class="fa fa-check"></i><b>14.3.3</b> EMA regulations on meling issues</a></li>
<li class="chapter" data-level="14.3.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#recent-examples-of-impact-of-pharmacometrics-in-decision-making"><i class="fa fa-check"></i><b>14.3.4</b> Recent examples of impact of pharmacometrics in decision making</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="15" data-path="asrm-2016.html"><a href="asrm-2016.html"><i class="fa fa-check"></i><b>15</b> ASRM 2016</a><ul>
<li class="chapter" data-level="15.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lectures"><i class="fa fa-check"></i><b>15.1</b> Plenary lectures</a><ul>
<li class="chapter" data-level="15.1.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-2"><i class="fa fa-check"></i><b>15.1.1</b> Plenary 2</a></li>
<li class="chapter" data-level="15.1.2" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lecture-3-the-importance-of-long-acting-reversible-contraception-larc"><i class="fa fa-check"></i><b>15.1.2</b> Plenary Lecture 3 : The importance of Long-acting reversible contraception (LARC)</a></li>
<li class="chapter" data-level="15.1.3" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-4"><i class="fa fa-check"></i><b>15.1.3</b> Plenary 4</a></li>
<li class="chapter" data-level="15.1.4" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-5"><i class="fa fa-check"></i><b>15.1.4</b> Plenary 5</a></li>
<li class="chapter" data-level="15.1.5" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-6-update-on-congenital-adrenal-hyperplasia"><i class="fa fa-check"></i><b>15.1.5</b> Plenary 6 Update on Congenital Adrenal Hyperplasia</a></li>
<li class="chapter" data-level="15.1.6" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-7---why-parents-matter-epigenetically-genomic-imprinting-in-health-and-disease"><i class="fa fa-check"></i><b>15.1.6</b> Plenary 7 - Why Parents Matter (Epigenetically): Genomic Imprinting in Health and Disease</a></li>
<li class="chapter" data-level="15.1.7" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-8-aua-bruce-stewart-memorial-lecture-the-futures-of-malereproductive-medicine"><i class="fa fa-check"></i><b>15.1.7</b> Plenary 8: AUA Bruce Stewart Memorial Lecture: The Futures of (Male(Reproductive)) Medicine</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="asrm-2016.html"><a href="asrm-2016.html#prize-oral"><i class="fa fa-check"></i><b>15.2</b> Prize Oral</a><ul>
<li class="chapter" data-level="15.2.1" data-path="asrm-2016.html"><a href="asrm-2016.html#mtor-inhibitors-preserve-fertility-in-a-murine-model-a-novel-pharmacologic-approach-to-fertility-preservation-during-gonadotoxic-chemotherapy"><i class="fa fa-check"></i><b>15.2.1</b> mTOR inhibitors preserve fertility in a murine model : a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy</a></li>
<li class="chapter" data-level="15.2.2" data-path="asrm-2016.html"><a href="asrm-2016.html#verification-of-accuracy-safety-for-ovarian-reserve-assessment-with-optical-coherence-tomography-using-mouse-ovary"><i class="fa fa-check"></i><b>15.2.2</b> Verification of accuracy &amp; safety for ovarian reserve assessment with optical coherence tomography using mouse ovary</a></li>
<li class="chapter" data-level="15.2.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-6-randomized-controlled-trial-of-low-5-vs.-ultralow-2-oxygen-tension-for-in-vitro-development-of-human-embryos"><i class="fa fa-check"></i><b>15.2.3</b> O-6 RANDOMIZED CONTROLLED TRIAL OF LOW (5%) VS. ULTRALOW (2%) OXYGEN TENSION FOR IN VITRO DEVELOPMENT OF HUMAN EMBRYOS</a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="asrm-2016.html"><a href="asrm-2016.html#symposium-overview-of-food-and-drug-administration-fda-regulations-of-products-used-to-treat-reproductive-conditions-in-women"><i class="fa fa-check"></i><b>15.3</b> Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women</a><ul>
<li class="chapter" data-level="15.3.1" data-path="asrm-2016.html"><a href="asrm-2016.html#richard-d.-mcfarland-m.d.-ph.d."><i class="fa fa-check"></i><b>15.3.1</b> Richard D. McFarland, M.D., Ph.D.</a></li>
<li class="chapter" data-level="15.3.2" data-path="asrm-2016.html"><a href="asrm-2016.html#rhonda---cder-drug-review-process"><i class="fa fa-check"></i><b>15.3.2</b> Rhonda - CDER Drug review process</a></li>
<li class="chapter" data-level="15.3.3" data-path="asrm-2016.html"><a href="asrm-2016.html#cdrh-center-for-devices-and-radiological-health"><i class="fa fa-check"></i><b>15.3.3</b> CDRH (Center for Devices and Radiological Health)</a></li>
<li class="chapter" data-level="15.3.4" data-path="asrm-2016.html"><a href="asrm-2016.html#endometriosis-tuesday-expo-theater"><i class="fa fa-check"></i><b>15.3.4</b> Endometriosis, Tuesday EXPO theater</a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="asrm-2016.html"><a href="asrm-2016.html#scientific-congress-prize-paper-session-2"><i class="fa fa-check"></i><b>15.4</b> Scientific Congress Prize Paper Session 2</a><ul>
<li class="chapter" data-level="15.4.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-91-preovulatory-protein-restriction-ppr-disrupted-amino-acid-aa-kinetics-and-mitochondrial-structure-and-function-in-the-rat-oocyte"><i class="fa fa-check"></i><b>15.4.1</b> O-91 PREOVULATORY PROTEIN RESTRICTION (PPR): DISRUPTED AMINO ACID (AA) KINETICS AND MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE RAT OOCYTE</a></li>
<li class="chapter" data-level="15.4.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-92-effects-of-resveratrol-on-polycystic-ovary-syndrome"><i class="fa fa-check"></i><b>15.4.2</b> O-92 EFFECTS OF RESVERATROL ON POLYCYSTIC OVARY SYNDROME</a></li>
<li class="chapter" data-level="15.4.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-93-genome-wide-dna-methylation-changes-in-mouse-zygotes-associated-with-superovulation"><i class="fa fa-check"></i><b>15.4.3</b> O-93 GENOME-WIDE DNA METHYLATION CHANGES IN MOUSE ZYGOTES ASSOCIATED WITH SUPEROVULATION</a></li>
<li class="chapter" data-level="15.4.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-94-can-we-expect-to-improve-age-at-menopause-predictions-with-repeated-amh-measurements"><i class="fa fa-check"></i><b>15.4.4</b> O-94 CAN WE EXPECT TO IMPROVE AGE AT MENOPAUSE PREDICTIONS WITH REPEATED AMH MEASUREMENTS?</a></li>
</ul></li>
<li class="chapter" data-level="15.5" data-path="asrm-2016.html"><a href="asrm-2016.html#oral-presentation"><i class="fa fa-check"></i><b>15.5</b> Oral Presentation</a><ul>
<li class="chapter" data-level="15.5.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-229-the-impact-of-elagolix-on-quality-of-life-in-women-with-endometriosis-associated-pain-results-from-two-randomized-placebo-controlled-studies-using-the-endometriosis-health-profile-questionnaire-hugh-taylor"><i class="fa fa-check"></i><b>15.5.1</b> O-229 THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE (Hugh Taylor)</a></li>
<li class="chapter" data-level="15.5.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-230-direct-and-indirect-costs-associated-with-endometriosis-related-surgery-among-employed-women-in-the-us"><i class="fa fa-check"></i><b>15.5.2</b> O-230 DIRECT AND INDIRECT COSTS ASSOCIATED WITH ENDOMETRIOSIS-RELATED SURGERY AMONG EMPLOYED WOMEN IN THE US</a></li>
<li class="chapter" data-level="15.5.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-231-new-procedure-for-the-endometriosis-diagnosis"><i class="fa fa-check"></i><b>15.5.3</b> O-231 NEW PROCEDURE FOR THE ENDOMETRIOSIS DIAGNOSIS</a></li>
<li class="chapter" data-level="15.5.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-232-elagolix-on-endometrium"><i class="fa fa-check"></i><b>15.5.4</b> O-232 Elagolix on endometrium</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="16" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html"><i class="fa fa-check"></i><b>16</b> KSCPT 2016 Fall</a><ul>
<li class="chapter" data-level="16.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#therapeutics-new-target"><i class="fa fa-check"></i><b>16.1</b> Therapeutics : New target</a><ul>
<li class="chapter" data-level="16.1.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#a-new-target-for-hiv-1-aids-drug"><i class="fa fa-check"></i><b>16.1.1</b> A new target for HIV-1 / AIDS drug</a></li>
<li class="chapter" data-level="16.1.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#new-drug-target-for-osteoporosis-gpr120"><i class="fa fa-check"></i><b>16.1.2</b> New drug target for osteoporosis: GPR120</a></li>
<li class="chapter" data-level="16.1.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#strategy-for-anti-cancer-target"><i class="fa fa-check"></i><b>16.1.3</b> Strategy for Anti-Cancer Target</a></li>
<li class="chapter" data-level="16.1.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>16.1.4</b> 재발자궁경부암 항암화학방사선 온열동시치료</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-i"><i class="fa fa-check"></i><b>16.2</b> Drug development I</a><ul>
<li class="chapter" data-level="16.2.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#non-clinical-considerations-for-fih"><i class="fa fa-check"></i><b>16.2.1</b> Non-clinical considerations for FIH</a></li>
<li class="chapter" data-level="16.2.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#------"><i class="fa fa-check"></i><b>16.2.2</b> 임상약리학 주도 환자 대상 초기임상시험의 경험과 전망</a></li>
<li class="chapter" data-level="16.2.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-contribution-of-clinical-pharmacologist-in-global-drug-development-real-examples-from-a-big-pharma"><i class="fa fa-check"></i><b>16.2.3</b> The Contribution of Clinical Pharmacologist in Global Drug Development: Real Examples from a Big Pharma</a></li>
</ul></li>
<li class="chapter" data-level="16.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-ii--"><i class="fa fa-check"></i><b>16.3</b> Drug development II 신상구 (차바이오컴플렉스)</a><ul>
<li class="chapter" data-level="16.3.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#babe------vs-"><i class="fa fa-check"></i><b>16.3.1</b> BA/BE 임상시험 결과분석 시 고려사항: 분산투여 vs 추가시험</a></li>
<li class="chapter" data-level="16.3.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-use-of-pharmacometrics-for-drug-development-in-korea"><i class="fa fa-check"></i><b>16.3.2</b> The use of pharmacometrics for drug development in Korea</a></li>
<li class="chapter" data-level="16.3.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#fatal-bia-10-2474-phase-i-clinical-trial-what-can-we-learn"><i class="fa fa-check"></i><b>16.3.3</b> Fatal BIA 10-2474 Phase I Clinical Trial : What Can We Learn?</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="17" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><i class="fa fa-check"></i><b>17</b> 2016-11-18 Will big data and data science reshape the horizon of drug development?, If so, how?</a><ul>
<li class="chapter" data-level="17.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#jscpt"><i class="fa fa-check"></i><b>17.1</b> JSCPT</a><ul>
<li class="chapter" data-level="17.1.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#--------"><i class="fa fa-check"></i><b>17.1.1</b> 대규모 약물 유도 전사체 정보 기반 항암 신약 재창출</a></li>
<li class="chapter" data-level="17.1.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#big-data-platform-for-multi-national-data-collaboration"><i class="fa fa-check"></i><b>17.1.2</b> Big data platform for multi-national data collaboration</a></li>
<li class="chapter" data-level="17.1.3" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#yoshinori-ochiai-pharmaceuticals-and-medical-devices-agency"><i class="fa fa-check"></i><b>17.1.3</b> Yoshinori Ochiai (Pharmaceuticals and Medical Devices Agency)</a></li>
<li class="chapter" data-level="17.1.4" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-big-data-national-registry-data-can-be-a-game-changer"><i class="fa fa-check"></i><b>17.1.4</b> How big data (national registry data) can be a game changer?</a></li>
</ul></li>
<li class="chapter" data-level="17.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-can-clinical-pharmacology-facilitate-collaboration-between-the-drug-development-industry-and-academia-particularly-in-the-asian-pacific-region"><i class="fa fa-check"></i><b>17.2</b> How can clinical pharmacology facilitate collaboration between the drug development industry and academia, particularly in the Asian-Pacific region?</a><ul>
<li class="chapter" data-level="17.2.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#thyroid"><i class="fa fa-check"></i><b>17.2.1</b> Thyroid</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="18" data-path="section.html"><a href="section.html"><i class="fa fa-check"></i><b>18</b> 2017-03-20</a></li>
<li class="chapter" data-level="19" data-path="reference.html"><a href="reference.html"><i class="fa fa-check"></i><b>19</b> Reference</a></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Summary of Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="acrep" class="section level1">
<h1><span class="header-section-number">Chapter 9</span> ACREP</h1>
<div id="observational-study" class="section level2">
<h2><span class="header-section-number">9.1</span> Observational Study</h2>
<ul>
<li>Speaker 이무송</li>
</ul>
<div id="contents" class="section level3">
<h3><span class="header-section-number">9.1.1</span> Contents</h3>
<ul>
<li>Cohort study</li>
<li>RR <span class="math display">\[ \frac{\frac{a}{a+b}}{\frac{c}{c+d}} \]</span></li>
<li>단점 - F/U loss, 재발에 대해서 연구 어렵다.</li>
<li>연구 대상 수 산출 방법 - Nomogram, 수식적용, 컴퓨터 PASS 2016</li>
<li>PCORI.org - conduct of Registry</li>
<li>Cohort는 F/U을 전제로 해서 한다. Retrospective Chart-review</li>
</ul>
</div>
</div>
<div id="observational-study-pitfall-----" class="section level2">
<h2><span class="header-section-number">9.2</span> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</h2>
<ul>
<li>Speaker: 임영석 교수님</li>
</ul>
<div id="experimental-study-yes" class="section level3">
<h3><span class="header-section-number">9.2.1</span> Experimental study? Yes</h3>
<div id="randomized-design-interventional--no" class="section level4">
<h4><span class="header-section-number">9.2.1.1</span> Randomized design? (interventional)- No</h4>
<ul>
<li>NR CLINICAL trial</li>
<li>Time series</li>
<li>PHASE 1</li>
</ul>
</div>
<div id="randomized-design-interventional--yes" class="section level4">
<h4><span class="header-section-number">9.2.1.2</span> Randomized design? (interventional)- Yes</h4>
<ul>
<li>Clinical Trial</li>
<li>Community Trial</li>
<li>Crossover design</li>
</ul>
</div>
</div>
<div id="experimental-study-no" class="section level3">
<h3><span class="header-section-number">9.2.2</span> Experimental study? No</h3>
<div id="comparison-group-no-observational-study" class="section level4">
<h4><span class="header-section-number">9.2.2.1</span> Comparison group? No = Observational study</h4>
<ul>
<li>Prevalence / incidence,</li>
<li>time trend,</li>
<li>case series,</li>
<li>case reoprt</li>
</ul>
</div>
<div id="comparison-group-yes-analytical-study" class="section level4">
<h4><span class="header-section-number">9.2.2.2</span> Comparison group? Yes = Analytical study</h4>
<ul>
<li>Cohort study,</li>
<li>case-control study,</li>
<li>cross-sectional study,</li>
<li>ecologic study,</li>
<li>PMS</li>
<li>두군을 비교하는가 안하는가가 중요한 기준이 된다.</li>
</ul>
</div>
</div>
<div id="contents-1" class="section level3">
<h3><span class="header-section-number">9.2.3</span> Contents</h3>
<ul>
<li>research question -(design)- study plan -(implement)- actual study</li>
<li>findings in the study -(infer)- truth in the study -(infer)- truth in the universe</li>
<li>위암, 대장, 폐암 - post op outcome을 통채로 비교하면 안된다.</li>
<li>internal validity &amp; external validity(generalization)</li>
<li>PICO anatomy #####</li>
<li>patient/population/problemn</li>
<li>Intervention</li>
<li>Comparison</li>
<li>Outcome</li>
<li>Gold standard of clinical studies - RCT</li>
<li>Sample - randomization (Treated / Control)</li>
<li>Research question - interesting, important, critical</li>
<li>Good research question - FINER - Feasible, Interesting, Novel, Ethical, Relevant</li>
<li>Feasible / Ethical / Relevant 가장 중요한 면</li>
<li>Prospective Cohort Study -</li>
<li>Case-control study - 뒤로 간다. 병원에서 case-control 하는 경우는 사망여부. Outcome인 경우가 많다. disease있고 없고가 아니라.</li>
<li>재발에 대한 - 환자군/대조군을 모아서. 그럼 어떻게 대조군 설정한건가?? 이런 것을 정할때 bias가 많이 발생하게 된다.</li>
<li>Historical cohort - Cohort assembled-(f/u)-&gt;Outcome</li>
<li>2000-2010 HCC 초치료 근치적 수술적 절제술 받은 환자들의 명단을 확보.</li>
<li>ITT analysis할때 반드시 필요하다.</li>
<li>5년 이상 관찰한 것이 있어.</li>
<li>Mimic those of clinical trials</li>
<li>Internal validity를 높여야 한다. restricted cohort / NEJM 2000;342:1887</li>
<li>IIT 분석을 해라.</li>
<li>Chance(Random Error) vs Bias(Systematic Error)</li>
<li>association / cause를 비교해야.</li>
<li>Confounder</li>
<li>biasd와는 좀 다르다. 미리 의식하고 물어보기 전엔 절대 알수 없다. 미리 질환에 대해 잘 알고있는 연구자여야만 찾을 수 있다.</li>
<li>Example : smoking - alcohol - heart disease</li>
<li>What is the effect of long-term tx(&gt;5y) with a potent oral antiviral agent(entecavir)(I) in patients with chronic hep B(P)</li>
<li>FDA, 식약처는 Surrogate marker를 가지고 허가를 내준다. (조직학적 개선,) - 이것과 환자의 outcome을 정말로 개선시키는건가? 이건 observational study에서만 찾을 수 있다. historical cohort</li>
<li>Zero time No treatment control</li>
<li>Endpoint ascertainment - 재발이 문제가 된다. 무엇으로 재발을 판정할 것인가? MR? CT? 검사간격을 얼마로 했니? 누구도 시비 못할 것으로 outcome measure하는 것이 좋다. (예를 들어 사망의 경우)</li>
<li>PP vs ITT</li>
<li>ITT - which treatment option is best at the time decision must be made? - FDA에서 ITT만 인정을 한다.</li>
<li>Explanatory</li>
<li>Multivariable Cox PH Analysis - (Event 수를 적어야 한다.) Univariate analysis만으로는 부족.</li>
<li>Multivariate analysis -</li>
<li>Propensity score - SPSS로 가능. 양군간 matching - 쌍을 갖춘다. 같은 수로 나온다. 이때는 univariate할 수 있다.</li>
<li>“consistently observed by unadjusted.” - obs study는 의심을 많이 받기 때문에. 이런 분석을 하는 것이 좋다.</li>
<li>Gadoxetic - liver specific contrast agent</li>
<li>2647patients-&gt;700명 수술 가능. - surrogate marker - CT에서 못본걸 MR에서 찾았다. | Cost-effectiveness - 무조건 survival. Propensity matching - Inverse Probability Weighing (IPTW)
<ol style="list-style-type: decimal">
<li>Unadjsted</li>
<li>mutivariable</li>
<li>IPTW</li>
<li>Propensity</li>
</ol></li>
<li>제목의 중요성. JCO (IF 21) - Hepatology (IF 11.7) - Gut (IF 14.921) (early rejection so far) - GE (IF 18.187) (accepted with more general terms in the title)</li>
</ul>
</div>
<div id="conclusion" class="section level3">
<h3><span class="header-section-number">9.2.4</span> Conclusion</h3>
<ul>
<li>mimic as closely as possible in RCT</li>
</ul>
</div>
</div>
<div id="diagnostic-test-biomarker-study" class="section level2">
<h2><span class="header-section-number">9.3</span> Diagnostic test &amp; Biomarker Study</h2>
<ul>
<li>Speaker: 박성호 - 영상의학과</li>
</ul>
<div id="contents---diagnostic-test" class="section level3">
<h3><span class="header-section-number">9.3.1</span> Contents - Diagnostic test</h3>
<ul>
<li>DTA sutdy</li>
<li>Prevalence낮으면</li>
<li>횡으로 본다. Predictive Value - Prevalence에 영향을 받는다. Pre올라가면 PPV올라가. NPV낮아져.</li>
<li>odds ratio - prevalence에 영향을 안받는다. intrinsic parameter로 많이 씀.</li>
<li>case-control study vs cross-sectional study [옛날 용어]</li>
<li>Cochrane - case-control type accuracy study vs cohort type accuracy study</li>
<li>NECA - diagnostic case-control study vs diagnostic cohort study</li>
<li>Area under ROC curve - C statistics</li>
<li>Youden index - sens spec 더해서 빼기 1 Youden J statistic</li>
<li>Least Euclidean distance from (0,1) 거리가 최소되는 점. - 쉬운개념</li>
<li>diagnostic accuracy - 시각적으로 어떻게 구성하는지가 중요함.</li>
<li>McNemar test</li>
<li>Comparing two proportions (2x2) - unpaired(fisher,Chi2), paired (McNemar)</li>
</ul>
</div>
<div id="contents---biomarker" class="section level3">
<h3><span class="header-section-number">9.3.2</span> Contents - Biomarker</h3>
<ul>
<li>Biomarker
<ul>
<li>Classifier / Prognostic / Predictive / Monitoring</li>
</ul></li>
<li>Petal et al. MRI-detected tumor response for locally advanced rectal cancer predicts survival outcomes</li>
<li>Machtay et al. Prediction of survival
<ul>
<li>Prospective</li>
<li>S III lung cancer eligible for CCRT</li>
<li>Endpoint : overall survival</li>
<li>SUV</li>
</ul></li>
<li>Hylton et al.
<ul>
<li>Prospective</li>
<li>Index: functional tumor volume measured with pre-surgery breast MRI</li>
<li>Comparator: post-surgical pathologic complete response(PCR)</li>
<li>Modified C-statistics(ROC) - diagnosis는 있다 없다로 나온다. survival은 time to event - 각각의 time point마다 diagnosis 유사한 통계량이 나와서 그걸 summation</li>
</ul></li>
<li>Studies of predictive accuracy
<ul>
<li>Two approaches - Time-to-event / event by a fixed time</li>
<li>Event by a fixed time - Sn Sp ROC - Accuracy study와 유사한 것으로 된다.</li>
</ul></li>
<li>더 impact있는 것. - randomization을 테스트 후에 할 것인가 아니면 전에 할 것인가? 전에 하는 것이 더 임팩트 있다. 왜냐하면 테스트(+)이면 치료 들어가는 경우가 많기 때문이다.</li>
<li>후자에 해당하는 (더 임팩트있는) 스터디의 예.</li>
<li>Monitoring biomarker
<ul>
<li>Correlation between x and y / delta x and delta y</li>
<li>Delta를 보는 것이 중요하다.</li>
</ul></li>
</ul>
</div>
</div>
<div id="----" class="section level2">
<h2><span class="header-section-number">9.4</span> 2차 자료원을 이용한 역학 연구군</h2>
<ul>
<li>Speaker: 예방의학교실/의학통계학과 김화정</li>
<li>NEJM 2006, BMI and mortality</li>
<li>이차자료원 : 특정한 연구목적으로 수집되지 않은 자료</li>
<li>공공데이터 - 정부</li>
<li>국건영 심평원 자료 - 생각보다 manage하기 쉽지 않다.</li>
<li>HIRA DB - 건강보험청구자료</li>
<li>NHISS 국민건강보험자료 공유서비스</li>
<li>보건의료 연구에 활용되는 공공데이터</li>
<li>장점 : 대규모자료, 장기간 추적관찰. 시간과 비용 절약</li>
<li>한국형 - outcomes Research</li>
<li>NECA에서 자료를 연계해 주겠다 라고 했으나.. 진전이 크지 않음</li>
<li>보건의료 빅데이터 개방시스템 - 공공데이터</li>
<li>명세서 일반내역 테이블</li>
<li>2차자료의 분석은 case-control의 기준 정하기가 어렵다. 금방 분석이 되기 힘듬. Crossvalidation 반드시 해야함.</li>
<li>과제신청 - 연구원등록 : 정부3.0에서 검토 자세히 하게됨.</li>
<li>SAS/R 프로그램.</li>
<li>단점 - 5년간의 자료. F/U보기가 힘들어. 진단명의 정확도 문제 - 70%. 에러의 숫자가 클 수 있음.</li>
<li>의학통계학과 공공데이터 연구지원 #4639 - 상담, 공공데이터 이용신청, 자료확보, 자료분석, 결과검토</li>
<li>NHISS 표본연구</li>
<li>Dramatic decrease in FQ in the pediatric population</li>
<li>case crossover design</li>
<li>indication bias - causality - association. confounding by indication</li>
</ul>
</div>
<div id="----clinical-prediction-model-individual-riskoutcome-probability--" class="section level2">
<h2><span class="header-section-number">9.5</span> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</h2>
<ul>
<li>Clinical prediction model</li>
<li>Framingham risk score</li>
<li>JAMA - moving from clinical trials to precision Medicine, 2016 Apr 26</li>
<li>DAPT Trial</li>
<li>Risk for advanced neoplasia and likelihood ratios in each risk group within derivation and validation sets <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840411/#!po=38.6364">Derivation and validation of a scoring system to stratify the risk of advanced colorectal neoplasia in asymptomatic adults</a> 분자:질병있는 / 분모:질병없는 - likelihood ratio</li>
<li>Assumptions for model development - linear regression, Cox proportional hazard regression(Proportionality of hazard ### This should be confirmed.)</li>
</ul>
<table style="width:11%;">
<colgroup>
<col width="2%" />
<col width="2%" />
<col width="2%" />
<col width="2%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>linear reg</th>
<th>logi reg</th>
<th>Cox reg</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Overall perf</td>
<td>R2</td>
<td>Nagelkerke r2, brir</td>
<td>the same</td>
</tr>
<tr class="even">
<td>discrimination ability</td>
<td></td>
<td>C concordance stat(AUC)</td>
<td>Harell C stat, time-dependent AUC</td>
</tr>
<tr class="odd">
<td>Calibratrion</td>
<td>Calibration plot, slope</td>
<td>the same+hosmer-lemeshow</td>
<td>the same</td>
</tr>
</tbody>
</table>
<ul>
<li>C-index 를 사용하여 분석 가능함. C = number of concordant pairs + 0.5/~~</li>
<li>새로운 통계 지표. 2가지. NRI - net eclassification improvement</li>
<li>Korean J Radiol 2016;17(3);339-350 -&gt; predicted probability - 사망할 확률을 계산할 수 있음.</li>
<li>Framingham그룹에서 발표됨 2008 통계 저널에</li>
</ul>
</div>
<div id="web-r.org" class="section level2">
<h2><span class="header-section-number">9.6</span> Web-r.org</h2>
<ul>
<li>Speaker: 문건웅 가톨릭대학교 성빈센트병원 심장내과</li>
</ul>
<div id="contents-2" class="section level3">
<h3><span class="header-section-number">9.6.1</span> Contents</h3>
<ul>
<li>web-r.org</li>
<li>로지스틱 리그레션 - 반응(종속)변수 - 설명변수 . 단변량 분석 먼저 나와 univariate logistic regression</li>
<li>다변량 분석.</li>
<li>생존분석 - 로지스틱 회귀분석과 비슷한것임. - 다른 것은 시간개념이 들어있는 것임. 얼마 있다가 돌아가셨는지 알 수 있음. KM 분석. cutpoint결정해줌.</li>
<li>나무분석 - 생존 나무 분석.</li>
<li>진단통계</li>
</ul>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="translation-and-convergence-for-future-medicine.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="prism-2016.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-24-ACREP.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
